N
Nicola Sgherza
Researcher at Casa Sollievo della Sofferenza
Publications - 76
Citations - 837
Nicola Sgherza is an academic researcher from Casa Sollievo della Sofferenza. The author has contributed to research in topics: Medicine & Myeloid leukemia. The author has an hindex of 14, co-authored 61 publications receiving 531 citations. Previous affiliations of Nicola Sgherza include University of Bari.
Papers
More filters
Journal ArticleDOI
Life after ruxolitinib: Reasons for discontinuation, impact of disease phase, and outcomes in 218 patients with myelofibrosis
Francesca Palandri,Massimo Breccia,Massimiliano Bonifacio,Nicola Polverelli,Elena Maria Elli,Giulia Benevolo,Mario Tiribelli,Elisabetta Abruzzese,Alessandra Iurlo,Florian H. Heidel,Micaela Bergamaschi,Alessia Tieghi,Monica Crugnola,Francesco Cavazzini,Gianni Binotto,Alessandro Isidori,Nicola Sgherza,Costanza Bosi,Bruno Martino,Roberto Latagliata,Giuseppe Auteri,Luigi Scaffidi,Davide Griguolo,Malgorzata Monika Trawinska,Daniele Cattaneo,Lucia Catani,Mauro Krampera,Roberto M. Lemoli,Antonio Cuneo,Gianpietro Semenzato,Robin Foà,Francesco Di Raimondo,Daniela Bartoletti,Michele Cavo,Giuseppe A. Palumbo,Nicola Vianelli +35 more
TL;DR: After discontinuing ruxolitinib, the outcome of patients with myelofibrosis reportedly has been poor and reasons for drug discontinuation, disease phase at discontinued drug, and salvage therapies may influence the outcome.
Journal ArticleDOI
Residual Peripheral Blood CD26+ Leukemic Stem Cells in Chronic Myeloid Leukemia Patients During TKI Therapy and During Treatment-Free Remission
Monica Bocchia,Anna Sicuranza,Elisabetta Abruzzese,Alessandra Iurlo,Santina Sirianni,Antonella Gozzini,Sara Galimberti,Lara Aprile,Bruno Martino,Patrizia Pregno,Federica Sorà,Giulia Alunni,Carmen Fava,Fausto Castagnetti,Luca Puccetti,Massimo Breccia,Daniele Cattaneo,Marzia Defina,Olga Mulas,Claudia Baratè,Giovanni Caocci,Simona Sica,Alessandro Gozzetti,Luigiana Luciano,Monica Crugnola,Mario Annunziata,Mario Tiribelli,Paola Pacelli,Ilaria Ferrigno,Emilio Usala,Nicola Sgherza,Gianantonio Rosti,Alberto Bosi,Donatella Raspadori +33 more
TL;DR: This cross-sectional study provides the first evidence that “circulating” CML LSCs persist in the majority of CML patients in molecular response while on TKI treatment and even after TKI discontinuation.
Journal ArticleDOI
Observational study of chronic myeloid leukemia Italian patients who discontinued tyrosine kinase inhibitors in clinical practice
Carmen Fava,Giovanna Rege-Cambrin,Irene Dogliotti,Marco Cerrano,Paola Berchialla,Matteo Dragani,Gianantonio Rosti,Fausto Castagnetti,Gabriele Gugliotta,Bruno Martino,Carlo Gambacorti-Passerini,Elisabetta Abruzzese,Chiara Elena,Patrizia Pregno,Antonella Gozzini,Isabella Capodanno,Micaela Bergamaschi,Monica Crugnola,Monica Bocchia,Sara Galimberti,Davide Rapezzi,Alessandra Iurlo,Daniele Cattaneo,Roberto Latagliata,Massimo Breccia,Michele Cedrone,Marco Santoro,Mario Annunziata,Luciano Levato,Fabio Stagno,Francesco Cavazzini,Nicola Sgherza,Valentina Giai,Luigia Luciano,Sabina Russo,Pellegrino Musto,Giovanni Caocci,Federica Sorà,Francesco Iuliano,Francesca Lunghi,Giorgina Specchia,Fabrizio Pane,Dario Ferrero,Michele Baccarani,Giuseppe Saglio +44 more
TL;DR: The experience within the Italian population confirms that discontinuation of imatinib and second generation TKI is feasible and safe in clinical practice.
Journal ArticleDOI
Arterial occlusive events in chronic myeloid leukemia patients treated with ponatinib in the real-life practice are predicted by the Systematic Coronary Risk Evaluation (SCORE) chart.
Giovanni Caocci,Olga Mulas,Elisabetta Abruzzese,Luigiana Luciano,Alessandra Iurlo,Immacolata Attolico,Fausto Castagnetti,Sara Galimberti,Nicola Sgherza,Massimiliano Bonifacio,Mario Annunziata,Antonella Gozzini,Ester Orlandi,Fabio Stagno,Gianni Binotto,Patrizia Pregno,Claudio Fozza,Malgorzata Monika Trawinska,Fiorenza De Gregorio,Daniele Cattaneo,Francesco Albano,Gabriele Gugliotta,Claudia Baratè,Luigi Scaffidi,Chiara Elena,Francesca Pirillo,Emilia Scalzulli,Giorgio La Nasa,Robin Foà,Massimo Breccia +29 more
TL;DR: Patients were stratified according to the Systematic Coronary Risk Evaluation (SCORE) assessment, based on sex, age, smoking habits, systolic blood pressure, and total cholesterol levels, and patients' AOEs were identified.
Journal ArticleDOI
Epidemiology, outcome, and risk factors for infectious complications in myelofibrosis patients receiving ruxolitinib: A multicenter study on 446 patients
Nicola Polverelli,Giuseppe A. Palumbo,Gianni Binotto,Elisabetta Abruzzese,Giulia Benevolo,Micaela Bergamaschi,Alessia Tieghi,Massimiliano Bonifacio,Massimo Breccia,Lucia Catani,Mario Tiribelli,Mariella D'Adda,Nicola Sgherza,Alessandro Isidori,Francesco Cavazzini,Bruno Martino,Roberto Latagliata,Monica Crugnola,Florian H. Heidel,Costanza Bosi,Adalberto Ibatici,Francesco Soci,Domenico Penna,Luigi Scaffidi,Franco Aversa,Roberto M. Lemoli,Umberto Vitolo,Antonio Cuneo,Domenico Russo,Michele Cavo,Nicola Vianelli,Francesca Palandri +31 more
TL;DR: Findings reinforce the concept of disease severity as the most important risk factor for infections, and describe, for the first time, that a positive therapeutic effect in reducing splenomegaly may also reduce subsequent infectious complications.